Abstract
Two types of radioiodinated plasma driven antigens, heat-inactivated (125I-h-HBsAg) and formalin-inactivated HBsAg (125I-f-HBsAg) were investigated for the effect of immunoadjuvant, aluminium phosphate (AP) on pharmacokinetics, organ distribution and humoral immunity of differently inactivated hepatitis B surface antigens (HBsAg) in rats. As a result, most of h-HBsAg (90%) was retained and slowly eliminated from the injection site. The h-HBsAg was highly localized in regional lymph node (RLN), but resulted in low humoral immune response. On the other hand, f-HBsAg was less localized in the injection site and RLN, but mainly distributed into serum and liver (62.9 and 22.4%, respectively). However, both h-HBsAg and f-HBsAg slowly disappeared from the injection site with AP, resulting in the increased area under the amount-time curve (AUQ) of h-HBsAg and f-HBsAg in the injection site. Exposures of h-HBsAg and f-HBsAg in serum were increased (1.4 and 2.8 times increase in AUC, respectively) with AP. The RLN uptake of both antigens were dramatically increased (25 and 3.1 times increase in AUC, respectively) with higher humoral immune response. The antibody titres were also increased with AP. In conclusion, pharmacokinetics, organ distribution and humoral immunity of h-HBsAg were highly dependent on the inactivation method of antigen and the presence of immunoadjuvant such as AP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bourquin, C., Anz, D., Zwiorek, K., Lanz, A. L., Fuchs, S., Weigel, S., Wurzenberger, C., von der Borch, P., Golic, M., Moder, S., Winter, G., Coester, C., and Endres, S., Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol., 181, 2990–2998 (2008).
De Temmerman, M. L., Rejman, J., Demeester, J., Irvine, D. J., Gander, B., and De Smedt, S. C., Particulate vaccine: on the quest for optimal delivery and immune response. Drug Discov. Today, 16, 569–582 (2011).
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., Larocque, D., Van Mechelen, M., and Garçon, N., AS04, an aluminum salt- and TLR4 agonistbased adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol., 183, 6186–6197 (2009).
Eickhoff, T. C. and Myers, M., Workshop summary, Aluminium in vaccines. Vaccine, 20, S1–S4 (2002).
Gonzalez, M. L., Usandizaga, M., Alomar, P., Salv’, F., Martin, F., Erroz, M. J., and Lardinois, R., Intradermal and intramuscular route for vaccination against hepatitis B. Vaccine, 8, 402–406 (1990).
Gupta, P. K. and Hung, C. T., Quantitative evaluation of targeted drug delivery systems, Int. J. Pharm., 56, 217–226 (1989).
Harlow, E. and Lane, D., Antibodies; a laboratory manual, Cold Spring Harbor Laboratory, New York, pp. 118–119, 324–329, (1988).
Henriksen-Lacey, M., Korsholm, K. S., Andersen, P., Perrie, Y., and Christensen, D., Liposomal vaccine delivery systems. Expert Opin. Drug Deliv., 8, 505–519 (2011).
HogenEsch, H., Mechanisms of stimulation of the immune response by aluminium adjuvants. Vaccine, 20, S34–S39 (2002).
Kim, C.-K. and Jeong, E. J., Development of dried liposomes as effective immune-adjuvant for hepatitis B surface antigen. Int. J. Pharm., 115, 193–199 (1995).
Kim, C.-K. and Jeong, E. J., Enhanced lymph node delivery and immunogenicity of hepatitis B surface antigen incorporated in galactosylated liposomes. Int. J. Pharm., 147, 143–151 (1997).
Kim, C.-K., Hwang, S. J, and Lee, M. G., The organ targetability of small and large albumin microspheres containing free and HSA conjugated methotrexate. Int. J. Pharm., 89, 91–102 (1993).
Kim, C.-K., Jeong, E. J., and Kim, M.-H., Comparison of in vivo fate and immunogenicity of hepatitis surface antigen incorporated in cationic and neutral liposomes. J. Microencapsul., 17, 297–306 (2000).
McKee, A. S., MacLeod, M. K., Kappler, J. W., and Marrack, P., Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol., 8, 37 (2010).
Munks, M. W., McKee, A. S., Macleod, M. K., Powell, R. L., Degen, J. L., Reisdorph, N. A., Kappler, J. W., and Marrack, P., Aluminium adjuvants elicit fibrin-dependent extracellular traps in vivo. Blood, 116, 5191–5199 (2010).
O’Hagan, D. T. and De Gregorio, E., The path to a successful vaccine adjuvant—’the long and winding road’. Drug Discov. Today, 14, 541–551 (2009).
Pandey, R. S. and Dixit, V. K., Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J. Drug Target., 18, 282–291 (2010).
Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E., and Bramwell, V. W., Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm., 364, 272–280 (2008).
Ravizzini, G., Turkbey, B., Barrett, T., Kobayashi, H., and Choyke, P. L., Nanoparticles in sentinel lymph node mapping. Nanomed. Nanobiotechnol., 1, 610–623 (2009).
Saini, V., Jain, V., Sudheesh, M. S., Jaganathan, K. S., Murthy, P. K., and Kohli, D. V., Comparison of humoral and cellmediated immune responses to cationic PLGA microspheres containing recombinants hepatitis B antigen. Int. J. Pharm., 408, 50–57 (2011).
Schüttler, C. G., Wend, U. C., Faupel, F. M., Lelie, P. N., and Gerlich W. H., Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg). J. Clin. Virol., 47, 238–242 (2010).
Segura, E. and Villadangos J. A., Antigen presentation by dendritic cells in vivo. Curr. Opin. Immunol., 21, 105–110 (2009).
Sun, H. X., Xie, Y., and Ye, Y. P., ISCOMs and ISCOMATRIX. Vaccine, 27 4388–4401 (2009).
Tabor, E., Buynak, E., Smallwood, L. A., Snoy, P., Hilleman, M., and Gerety, R. J., Interaction of hepatitis B virus by three methods: treatment with pepsin, urea, or formalin. J. Med. Virol., 11, 1–9 (1983).
von Andrian, U. H. and Mempel, T. R., Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol., 3, 867–878 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jeong, E.J., Maeng, HJ., Lee, HJ. et al. Effect of adjuvant on pharmacokinetics, organ distribution and humoral immunity of hepatitis b surface antigen after intramuscular injection to rats. Arch. Pharm. Res. 35, 1621–1628 (2012). https://doi.org/10.1007/s12272-012-0913-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-012-0913-1